466 related articles for article (PubMed ID: 26721645)
1. Ivabradine: Heart Failure and Beyond.
Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
[TBL] [Abstract][Full Text] [Related]
2. Advances in the management of heart failure: the role of ivabradine.
Müller-Werdan U; Stöckl G; Werdan K
Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
[TBL] [Abstract][Full Text] [Related]
3. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
4. Role of the Funny Current Inhibitor Ivabradine in Cardiac Pharmacotherapy: A Systematic Review.
Petite SE; Bishop BM; Mauro VF
Am J Ther; 2018; 25(2):e247-e266. PubMed ID: 26910057
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine in Management of Heart Failure: a Critical Appraisal.
Orasanu G; Al-Kindi SG; Oliveira GH
Curr Heart Fail Rep; 2016 Feb; 13(1):60-9. PubMed ID: 26797824
[TBL] [Abstract][Full Text] [Related]
7. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.
Nuding S; Ebelt H; Hoke RS; Krummenerl A; Wienke A; Müller-Werdan U; Werdan K
Clin Res Cardiol; 2011 Oct; 100(10):915-23. PubMed ID: 21638157
[TBL] [Abstract][Full Text] [Related]
8. Ivabradine.
Komajda M
Handb Exp Pharmacol; 2017; 243():167-175. PubMed ID: 27752846
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
[TBL] [Abstract][Full Text] [Related]
10. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
11. The Use and Indication of Ivabradine in Heart Failure.
Dodd K; Lampert BC
Heart Fail Clin; 2018 Oct; 14(4):493-500. PubMed ID: 30266358
[TBL] [Abstract][Full Text] [Related]
12. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
13. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
[TBL] [Abstract][Full Text] [Related]
14. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
15. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Chow SL; Page RL; Depre C
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
[TBL] [Abstract][Full Text] [Related]
16. [Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies].
Vítovec J; Spinarová L; Spinar J
Vnitr Lek; 2012; 58(7-8):612-17. PubMed ID: 23067195
[TBL] [Abstract][Full Text] [Related]
17. Update on ivabradine for heart failure.
Borer JS; Tavazzi L
Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
[TBL] [Abstract][Full Text] [Related]
18. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
[TBL] [Abstract][Full Text] [Related]
19. Inappropriate sinus tachycardia: focus on ivabradine.
Abed HS; Fulcher JR; Kilborn MJ; Keech AC
Intern Med J; 2016 Aug; 46(8):875-83. PubMed ID: 27059112
[TBL] [Abstract][Full Text] [Related]
20. The funny current: cellular basis for the control of heart rate.
DiFrancesco D; Borer JS
Drugs; 2007; 67 Suppl 2():15-24. PubMed ID: 17999560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
